Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Uschner, Frank E ^a   Ranabhat, Ganesh ^a   Choi, Steve S ^b   Granzow, Michaela ^a   Klein, Sabine ^a   Schierwagen, Robert ^a   Raskopf, Esther ^a   Gautsch, Sebastian ^a   Van Der Ven, Peter F M ^a   Fürst, Dieter O ^a   Strassburg, Christian P ^a   Sauerbruch, Tilman ^a   Mae Diehl, Anna ^b   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SONIC HEDGEHOG PROTEIN;

ANIMAL; BIOLOGICAL MODEL; CELL LINE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEMODYNAMICS; HEPATIC STELLATE CELL; HUMAN; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOPHYSIOLOGY; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS; CELL LINE; DISEASE MODELS, ANIMAL; HEDGEHOG PROTEINS; HEMODYNAMICS; HEPATIC STELLATE CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84942436651     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14573     Document Type: Article

References (47)

1. Friedman, S. L. Mechanisms of Hepatic Fibrogenesis. Gastroenterology 134, 1655-1669 (2008).
2. Sanyal, A. J., Bosch, J., Blei, A. & Arroyo, V. Portal hypertension and its complications. Gastroenterology 134, 1715-1728 (2008).
3. Bosch, J. & García-Pagán, J. C. Complications of cirrhosis. I. Portal hypertension. J. Hepatol. 32, 141-156 (2000).
4. Van de Casteele, M., Sägesser, H., Zimmermann, H. & Reichen, J. Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. Pharmacol. Ther. 90, 35-43 (2001).
5. Groszmann, R. J. & Abraldes, J. G. Portal hypertension: from bedside to bench. J. Clin. Gastroenterol. 39, S125-130 (2005).
6. Darwish Murad, S. et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann. Intern. Med. 151, 167-175 (2009).
7. Plessier, A. et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 51, 210-218 (2010).
8. Seijo, S. et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology 57, 1962-1968 (2013).
9. Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651-1658 (2009).
10. Laufs, U. & Liao, J. K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266-24271 (1998).
11. Laufs, U., Marra, D., Node, K. & Liao, J. K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J. Biol. Chem. 274, 21926-21931 (1999).
12. Rikitake, Y. & Liao, J. K. Rho GTPases, statins, and nitric oxide. Circ. Res. 97, 1232-1235 (2005).
13. Trebicka, J. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46, 242-253 (2007).
14. Trebicka, J. et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J. Hepatol. 53, 702-712 (2010).
15. Klein, S. et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab. Invest. 92, 1440-1450 (2012).
16. Marrone, G. et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut (2014). doi: 10.1136/gutjnl-2014-308338.
17. Chinchilla, P., Xiao, L., Kazanietz, M. G. & Riobo, N. A. Hedgehog proteins activate pro-angiogenic responses in endothelial cells through non-canonical signaling pathways. Cell Cycle 9, 570-579 (2010).
18. Renault, M.-A. et al. Sonic hedgehog induces angiogenesis via Rho kinase-dependent signaling in endothelial cells. J. Mol. Cell. Cardiol. 49, 490-498 (2010).
19. Omenetti, A., Choi, S., Michelotti, G. & Diehl, A. M. Hedgehog signaling in the liver. J. Hepatol. 54, 366-373 (2011).
20. Beachy, P. A., Hymowitz, S. G., Lazarus, R. A., Leahy, D. J. & Siebold, C. Interactions between Hedgehog proteins and their binding partners come into view. Genes Dev. 24, 2001-2012 (2010).
21. Choi, S. S. et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J. Biol. Chem. 285, 36551-36560 (2010).
22. Jung, Y. et al. Signals from dying hepatocytes trigger growth of liver progenitors. Gut 59, 655-665 (2010).
23. Omenetti, A. & Diehl, A. M. Hedgehog signaling in cholangiocytes. Curr. Opin. Gastroenterol. 27, 268-275 (2011).
24. Omenetti, A. et al. Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. Lab. Invest. 87, 499-514 (2007).
25. Yang, L. et al. Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J. Hepatol. 48, 98-106 (2008).
26. Beachy, P. A. et al. Multiple roles of cholesterol in hedgehog protein biogenesis and signaling. Cold Spring Harb. Symp. Quant. Biol. 62, 191-204 (1997).
27. Cooper, M. K., Porter, J. A., Young, K. E. & Beachy, P. A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280, 1603-1607 (1998).
28. Liang, C.-C., Park, A. Y. & Guan, J.-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2, 329-333 (2007).
29. Choi, S. S. et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G1093-1106 (2009).
30. Maitah, M. Y., Ali, S., Ahmad, A., Gadgeel, S. & Sarkar, F. H. Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS ONE 6, e16068 (2011).
31. Abraldes, J. G. et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J. Hepatol. 46, 1040-1046 (2007).
32. Xie, G. et al. Hedgehog signalling regulates liver sinusoidal endothelial cell capillarisation. Gut 62, 299-309 (2013).
33. Pola, R. et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 7, 706-711 (2001).
34. Pinter, M. et al. Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma. United European Gastroenterol J 1, 265-275 (2013).
35. Zafra, C. et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126, 749-755 (2004).
36. Simon, T. G., King, L. Y., Zheng, H. & Chung, R. T. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J. Hepatol. (2014). doi: 10.1016/j.jhep.2014.08.013.
37. Trebicka, J. et al. Role of β3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 50, 1924-1935 (2009).
38. Resch, M. et al. Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G849-857 (2009).
39. Wiest, R. et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J. Clin. Invest. 104, 1223-1233 (1999).
40. Grace, J. A. et al. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 145, 874-884 .e5 (2013).
41. Trebicka, J. et al. Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. Liver Int. 31, 860-870 (2011).
42. Huss, S. et al. Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis. Fibrogenesis Tissue Repair 3, 10 (2010).
43. Trebicka, J. et al. Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. Liver Int. (2014). doi: 10.1111/liv.12613.
44. Wojtalla, A. et al. The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G873-887 (2012).
45. Granzow, M. et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 60, 334-348 (2014).
46. Raskopf, E. et al. Toxic damage increases angiogenesis and metastasis in fibrotic livers via PECAM-1. Biomed Res Int 2014, 712893 (2014).
47. Schmitz, V. et al. Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model. Gut 56, 271-278 (2007).